Evidence map›Paper›PMID 35792831›Full record

ArticleThe journal of spinal cord medicine2023

Intravesical hyaluronic acid with chondroitin sulphate to prevent urinary tract infection after spinal cord injury.

Gabrielle K King, Louise M Goodes, Carly Hartshorn, Jeffery Thavaseelan, Sheryl Jonescu, Anne Watts, Matthew Rawlins, Peter Woodland, Emma-Leigh Synnott, Trent Barrett and 3 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of spinal cord medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03945110 (Intravesical Glycosaminoglycan Instillation Following Spinal Cord Injury and Early Urinary Tract Infections; Safety and Feasibility Study), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03945110 phase1 / phase2completednot on this map

Intravesical Glycosaminoglycan Instillation Following Spinal Cord Injury and Early Urinary Tract Infections; Safety and Feasibility Study

TypeinterventionalSponsorThe University of Western AustraliaRan2019 to 2021Enrolled10ConditionsSpinal Cord InjuriesArmsiAluRil® intravesical instillations
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Gabrielle K KingSchool of Biological Sciences, The University of Western Australia, Crawley, WA, Australia.
Louise M GoodesSchool of Biological Sciences, The University of Western Australia, Crawley, WA, Australia.
Carly HartshornPerth Urology Clinic, Murdoch, WA, Australia.
Jeffery ThavaseelanPerth Urology Clinic, Murdoch, WA, Australia.
Sheryl JonescuDepartment of Trauma, Royal Perth Hospital, Perth, WA, Australia.
Anne WattsState Rehabilitation Service, Fiona Stanley Hospital, Murdoch, WA, Australia.
Matthew RawlinsDepartment of Pharmacy, Fiona Stanley Hospital, Murdoch, WA, Australia.
Peter WoodlandDepartment of Spinal Surgery, Royal Perth Hospital, Perth, WA, Australia.
Emma-Leigh SynnottState Rehabilitation Service, Fiona Stanley Hospital, Murdoch, WA, Australia.
Trent BarrettDepartment of Urology, Fiona Stanley Hospital, Murdoch, WA, Australia.
Dickon HayneDepartment of Urology, Fiona Stanley Hospital, Murdoch, WA, Australia.
Peter BoanDepartment of Infectious Diseases, Fiona Stanley Hospital, Murdoch, WA, Australia.ORCID 0000-0002-0518-0421
Sarah A DunlopSchool of Biological Sciences, The University of Western Australia, Crawley, WA, Australia.
Fiona Stanley Hospital · AUThe University of Western Australia · AUMurdoch University · AURoyal Perth Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CONTEXT/

objectivePrevention of urinary tract infection (UTI) after spinal cord injury is an important goal. Intravesical hyaluronic acid with chondroitin sulphate (HA+CS) has been effective in preventing UTI in other settings. We aimed to demonstrate safety and feasibility of a standard treatment course of 7 intravesical HA+CS instillations over 12 weeks, in patients with acute (Arm A) and chronic (Arm B) spinal cord injury (SCI).

designFollow-up of adverse events, quality of life bladder management difficulty (BMD) and bladder complication (BC)

resultsOf 33 and 14 individuals screened, 2 and 8 participants were recruited to the study for Arm A and Arm B respectively. Of the 10 participants, 8 completed all 7 instillations. HA+CS commonly caused cloudy urine with urinary sediment which was mild and short-lived. In Arm B, a mean reduction in BMD and BC T-scores was observed from baseline (57.3 and 54.4 respectively), of 6.8 and 4.3 at 12 weeks and 1.6 and 2.8 at 24 weeks, respectively. Four participants with a history of frequent UTI in the prior 12 months did not have UTI in the 24 weeks of the study.

conclusionsHA+CS was well tolerated. Recruitment was more difficult in early acute SCI; participants with chronic SCI were highly motivated to reduce UTI and manage self-administration without difficulty. Larger case-control or randomized controlled trials in patients with neurogenic bladder from SCI are warranted.

trial registrationClinicalTrials.gov identifier: NCT03945110.

Indexed as

Spinal Cord InjuriesUrinary Tract InfectionsChondroitin SulfatesHumansHyaluronic AcidQuality of LifeChondroitin SulfatesHyaluronic AcidChondroitin sulphateHyaluronic acidSpinal cord injuryUrinary tract infectionUTI

Identifiers

PMID35792831
PMCPMC10446783
OpenAlexW4283830712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.